Immunic Announces Participation in February Conferences
Immunic, Inc. (Nasdaq: IMUX), a pioneering biotechnology firm, is gearing up to present its latest advancements in drug development at several key investor and scientific conferences throughout February. These events will provide an excellent platform for sharing insights on their innovative therapies aimed at addressing chronic inflammatory and autoimmune diseases.
Upcoming Events Featuring Immunic
The conferences where Immunic will be participating include:
- February 10-11: The BIO CEO & Investor Conference 2025, where Daniel Vitt, Ph.D., CEO of Immunic, will engage in one-on-one meetings. This event promises valuable discussions on the evolving landscape of biotechnology and therapeutics.
- February 11-12: The Oppenheimer 35th Annual Healthcare Life Sciences Conference. Dr. Vitt will also participate in a fireside chat, offering insights into Immunic's vision and progress in clinical development.
- February 19-22: The 19th Congress of the European Crohn's and Colitis Organisation (ECCO) in Berlin. Immunic's scientific team will present two impactful abstracts related to their flagship drug, IMU-856, focused on regenerative therapies.
- February 25-27: The 7th Neuroimmunology Drug Development Summit in Boston, where Hella Kohlhof, Ph.D., will showcase their leading therapy, vidofludimus calcium (IMU-838), exploring its combined neuroprotective and anti-inflammatory capabilities.
- February 27 - March 1: The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025. Immunic's team will provide insights from two accepted poster presentations, further advancing discussions on multiple sclerosis treatments.
Highlighting Immunic's Groundbreaking Research
At these conferences, Immunic will highlight its lead programs, notably vidofludimus calcium (IMU-838), which is in pivotal trials targeting relapsing and progressive forms of multiple sclerosis. This therapy harnesses a dual mechanism, acting as a nuclear receptor related 1 (Nurr1) activator while inhibiting dihydroorotate dehydrogenase (DHODH) to produce both neuroprotective and anti-inflammatory effects.
Additionally, the conference presentations will cover IMU-856, a novel orally administered modulator designed to enhance intestinal barrier integrity and support bowel health. Its investigational applications also extend to autoimmune disorders, showcasing its potential in treating various gastrointestinal conditions.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) continues to innovate in the field of biotechnology, developing a rich pipeline of orally available therapies tailored for chronic inflammatory and autoimmune diseases. Their commitment to research excellence positions them uniquely in the industry, promising advancements that can significantly improve patient outcomes. With lead candidates in late-stage clinical trials, Immunic's efforts are aligned with unmet medical needs.
For further context on their developments, the public can explore updates on Immunic's website, which offers an extensive overview of their ongoing clinical trials, therapeutic pipelines, and conference participation details.
Frequently Asked Questions
What is the focus of Immunic, Inc.'s research?
Immunic focuses on developing orally available therapies specifically for chronic inflammatory and autoimmune diseases.
Which major conferences will Immunic be attending?
Immunic will attend several conferences, including the BIO CEO & Investor Conference and the ECCO Congress.
What are the main drugs featured by Immunic at the conferences?
Immunic will primarily feature its lead drug, vidofludimus calcium (IMU-838), and another candidate, IMU-856.
What potential conditions do these drugs target?
These drugs target conditions like multiple sclerosis and other chronic inflammatory disorders.
How can I learn more about Immunic's products and research?
More information can be found on Immunic’s official website, detailing their pipeline and clinical developments.
